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and an increase in free zinc. Redox stress is thought to affect many 
intracellular metabolic processes including inhibition of reductases and, 
ultimately, induction of cell death. Oxidative stress induced by MGd 
appears to exceed the NRF-2 mediated antioxidant capacity in A549 
lung cancer cells. The mechanism of action and activity of MGd may 
be particularly well suited for therapy of NSCLC.
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Serum biomarkers predict response to combination celecoxib and 
erlotinib therapy in advanced non-small cell lung cancer
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Background: Cyclooxygenase-2 (COX-2) overexpression may 
mediate resistance to EGFR TK inhibition through prostaglandin E2 
(PGE2)-dependent promotion of epithelial to mesenchymal transition 
(EMT). The suppression of epithelial markers such as E-cadherin can 
to non-small cell lung cancer (NSCLC) resistance to erlotinib. In addi-
tion, PGE2 can downregulate E-cadherin expression by upregulating 
the transcriptional repressors of E-cadherin, ZEB1 and Snail. These 
ﬁndings suggest that COX-2 inhibition may enhance the efﬁcacy of 
EGFR TKI therapy in NSCLC, and markers of EMT may be important 
in predicting response to this combination of targeted therapy. 
Methods: A phase I, dose escalation trial to was performed investigat-
ing the combination of celecoxib and erlotinib in patients with ad-
vanced NSCLC. Soluble E-cadherin was evaluated by ELISA in patient 
serum at baseline and weeks 4 and 8 of treatment. Other markers of 
COX-2 gene expression and EMT were evaluated by ELISA, including 
matrix metalloproteinase (MMP)-9, MMP-2, tissue inhibitor of MMP 
(TIMP1), and CCL15. 
Results: 22 patients had serum samples available for evaluation. Serum 
E-cadherin, MMP-9, MMP-2, TIMP1 and CCL15 were analyzed 
according to best response (PR, SD or PD). We found a signiﬁcant 
decrease in soluble E-cadherin between baseline and week 8 in pts with 
PR when compared to those with SD or PD (p = 0.021). In patients 
who responded to the combination therapy, baseline MMP-9 was sig-
niﬁcantly lower compared to non-responders (p = 0.006). MMP-2 and 
TIMP1 showed no signiﬁcant change based on patient response, and 
CCL15 decreased in patients with PR. 
Conclusions: Soluble E-cadherin, MMP-9 and other downstream 
markers of COX-2 gene expression may be useful for assessing 
response to combination celecoxib and erlotinib in pts with advanced 
NSCLC. A randomized Phase II trial is planned comparing erlotinib 
and celecoxib with erlotinib plus placebo in advanced NSCLC, to 
evaluate the efﬁcacy of this combination therapy and to assess these 
and other biomarkers in both serum and tumor tissue. 
Supported by Phase One Foundation Award, UCLA Lung Cancer 
SPORE NCI P50 CA 90388 and GLAVAHS CDA. 
P3-034 NT: Molecular Therapeutics Posters, Wed, Sept 5 – Thur, Sept 6 
Combined 131I-chTNT and external irradiation for solid tumors in 
the mouse
Wu, Gang 
Union Hospital, Wu Han, China
Objective: To compare the difference of only 131I-chTNT and 
combined 131I-chTNT and external irradiation for solid tumors in the 
mouse. 
Methods: chTNT-3, a chemic monoclonal antibody directed cell 
nucleus in the necrotic parts of tumor, can play important roles in many 
tumors. chTNT-3 is iodinated with 131I. Among twenty-four nude mice 
with tumor cells xenografts(human adenocarcinoma of lung) used in 
the study, were divided into six groups and given different treatment 
protocols. Total accumulated dose, 24h percentage of injected activity 
per gram of tumor tissue and accumulated dose per injected activity 
were compared between there different groups. 
Results: In the study, better yields in terms of total accumulated dose, 
24h percentage of injected activity per gram of tumor tissue and accu-
mulated dose per injected activity were seen in the ﬁrst group. 
Conclusions: Enhanced effects can be achieved by combined external 
irradiation with radioimmunotherapy using the monoclonal anticyto-
keratin antibody 131 I-chTNT. 20Gy of external irradiation should be 
given prior to Mab injection.
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soluble vascular endothelial growth factor receptor 1( s VEGFR1) 
transducted by sendai virus using dendritic cells as vector inhibited 
HUVEC activity in vitro and growth and metastasis of Lewis lung 
cancer in vivo
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Objective: To evaluate the anticancer effect of s VEGFR1 transducted 
by sendai virus using dendritic cells(DCs) as vector in vitro and in vivo
Methods: Isolated and puriﬁed mouse bone marrow derived DCs were 
infected by sendai viruses at different moi, which were transducted by 
s VEGFR1(s VEGFR1-SeV-DCs). The culture medium was collected 
to treat HUVEC in vitro to analysis the proliferation, apoptosis, s 
VEGFR1-SeV-DCs were injected to Lewis lung cancer bearing mice to 
evaluate the survival time, growth and metastasis in vivo.
Results: s VEGFR1-SeV-DCs inhibited the proliferation of HUVEC, 
and induced apoptosis in vitro, s VEGFR1-SeV-DCs inhibited the 
growth and metastasis of Lewis lung cancer in vivo, and inhibited 
proliferation of lung cancer, induced apoptosis of cancer cells and 
inhibited the angiogenesis and improved immunological response.
Conclusions: SeV-DC was an effective vector in immuno-gene 
therapy, s VEGFR1 was an interesting gene in gene therapy, it is need 
to be studied further in future.
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Combination of low-dose chemotherapy with intratumoral 
dendritic cell vaccine is beneficial for the treatment of murine non 
small cell lung cancer
Zhong, Hua 
Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, 
China
At present study, we evaluated an antitumor potential of low- dose che-
motherapy combined with intratumoral dendritic cells (DC) vaccine in 
the s.c. murine Lewis lung cancer model. The dose of chemotherapeu-
